Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | GCK | P35557 | 2/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
| ▸ | VEGFA | P15692 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863295 | 0.77 | CYP1A1 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4CYP3A4 | |
| SCHEMBL91463 | 0.76 | — | — | |
| SCHEMBL29465753 | 0.76 | — | — | |
| SCHEMBL875081 | 0.73 | CHRNB2 (0.46) | CHRNB2CHRNA4 | |
| SCHEMBL1865390 | 0.73 | HCAR2 (0.38) | HCAR2CYP3A4VEGFA | |
| SCHEMBL28487252 | 0.73 | ATM (0.38) | ATMCHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2215868 | 0.72 | CHRNB2 (0.43) | CHRNB2CHRNA4GCK | |
| SCHEMBL2214269 | 0.72 | CYP11B1 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1866648 | 0.72 | CYP11B1 (0.33) | — | |
| SCHEMBL364636 | 0.72 | ALDH1A1 (0.44) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120091815-A | T-type voltage-gated calcium channel enhancer | 广泛研究所股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-118515663-A | Imidazopyridine or imidazopyrazine compounds, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-117279896-A | Amino substituted pyrido ring compounds, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-116848107-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116685583-A | Pyrimidine compounds, compositions and pharmaceutical uses thereof | 缆图药品公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116490503-A | Casein kinase 1 delta modulators | 詹森药业有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-112585128-B | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| CN-115531387-A | Pyrazole amide compounds useful as IRAK inhibitors | 里格尔药品股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-110234637-B | Pyrazole amide compounds useful as IRAK inhibitors | 里格尔药品股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-114269730-A | 5-heteroaryl-pyridin-2-amine compounds as neuropeptide FF receptor antagonists | 多曼治疗学公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-2493877-B1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-17 | — | — | EP | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20130310358-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-21 | — | — | US | disclosed |
| US-8513271-B2 | Pyrimidine compounds as delta opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-20 | — | — | US | disclosed |
| EP-2493877-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20110178065-A1 | NOVEL CYP17 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011088160-A2 | NOVEL CYP17 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011053705-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
| US-20110105520-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178065-A1 | NOVEL CYP17 INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | ATM 2990/4885CHRNB1 2251/4885CHRNB2 3446/4885 |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | CYP11B1, HSD11B1, CYP11B2 | ATM 4741/4885CHRNB1 281/4885CHRNB2 757/4885 |
| US-20110105520-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | OPRD1, OPRK1, OPRM1 | ATM 3381/4885CHRNB1 199/4885CHRNB2 334/4885 |
| US-20130310358-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | OPRD1, OPRK1, OPRM1 | ATM 3381/4885CHRNB1 199/4885CHRNB2 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.